A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

What this study is about

This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.

Who can join (things the study team will check)

✅ You may be able to join if…

• Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma
• Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
• Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70.
• Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 / Lugano criteria and documented by computed tomography (CT) and / or magnetic resonance imaging (MRI)

🚫 You may not be able to join if…

• Received treatment with another RBM39 degrader
• Clinically significant gastrointestinal (GI) or GI malabsorption

Where this trial is running

• City of Hope, Duarte, California, United States
• Cleveland Clinic, Cleveland, Ohio, United States
• SCRI Oncology Partners - PPDS, Nashville, Tennessee, United States
• START Mountain Region, West Valley City, Utah, United States
• Princess Margaret Cancer Centre, Toronto, Ontario, Canada
• McGill University Health Centre (MUHC) - The Montreal, Québec, Canada